$IRTC

Shrishrimal Sumi sold $670K of IRTC

Shrishrimal Sumi (EVP, Chief Risk Officer) sold 5,372 shares of iRhythm Holdings, Inc. (IRTC) at $124.65 ($0.67M total) on 2026-08-10.

Original reporting
SEC EDGAR · Shrishrimal Sumi
Published Aug 11, 2026, 8:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 8:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$IRTC
Neutral
low confidence
Mentioned
$IRTC
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IRTCNeutralLow
01

Why it matters

The newest fact is the specific open-market sale size, price, and post-transaction holdings of the company’s EVP Chief Risk Officer.

02

Market read

Traders may note insider selling as a minor sentiment input, but there is no new operational or financial guidance in the text.

03

What to watch

The article lacks context on total holdings, prior sales cadence, and whether the sale was tax-related or part of a broader personal liquidity event.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-11 after-hours; sale dated 2026-08-10

Background

The article is an SEC Form 4 insider transaction disclosure for iRhythm Holdings, Inc. (IRTC).

Company-level read

Ticker impact

$IRTCNeutralLow confidence
Context

Form 4 shows IRTC EVP Chief Risk Officer Shrishrimal Sumi sold 5,372 shares for about $669.6K at $124.6539 on 2026-08-10.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and small versus broader fundamentals.

Evidence & confidence

The filing is a Form 4 insider transaction, which often has non-informational motives; the article provides no accompanying guidance, legal, or operational change.

Market effects

No sector-level read-through; this is company-specific insider trading disclosure.

None indicated.

None indicated.

Counterpoint

Insider sales can be planned for liquidity or diversification; absence of a stated 10b5-1 plan does not necessarily imply negative information.

Key entities

  • iRhythm Holdings, Inc.

    Public company subject of the Form 4 insider transaction disclosure.

  • Shrishrimal Sumi

    EVP, Chief Risk Officer who sold 5,372 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$RMDMedAI 8/10

Patient Monitoring Stocks Q2 Teardown: ResMed (NYSE:RMD) Vs The Rest

ResMed (RMD) and peers reported Q2 earnings, with revenues beating estimates by 1.4% but next quarter's guidance below. RMD's revenue grew 8.6% YoY, meeting expectations, while iRhythm (IRTC) saw 20.1% growth, exceeding estimates. Insulet (PODD) and DexCom (DXCM) also reported, with mixed results. Stocks have declined since earnings, with RMD down 2.3% and IRTC down 13%.

$IRTCMedAI 9/10

iRhythm (IRTC) Q2 2026 Earnings Call Transcript

iRhythm (IRTC) reported Q2 2026 revenue of $224.2M, up 20.1% YoY, with gross margin at 72.8%. GAAP net loss was $0.4M, and adjusted EBITDA was $43.3M. Full-year revenue guidance is $880M to $890M and adjusted EBITDA margin 13% to 14%. The company agreed to acquire VitalConnect for about $287.5M and received a $50M Baxter settlement.